Swiss-based Addex Therapeutics – which has recently rebounded from a financial crisis – hopes a partnership deal with Indivior to develop new addiction treatments will give it adequate money, time and needed profiling to attract other partners for progressing its proprietary pipeline, notably its lead asset dipraglurant.
Founded in 2002, Addex is developing oral therapies for neurological disorders, targeting the GABAb receptor pathway in the brain
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?